

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

Table 01: Study population and enrolment information
Full Analysis Dataset : RUSSIA

Number of prospective patients (C1+C2+C3+C4+C5)	2128
Number of enrolling sites	36
Number of enrolling countries	1
Enrolment period	29JUN2012 - 26JUL2016
Duration of enrolment (months)	48.9

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : RUSSIA**

Region	Country	Cohort 2 (N=586)	Cohort 3 (N=645)	Cohort 4 (N=425)	Cohort 5 (N=472)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Europe	Russia	586	645	425	472	2128	1656

**Table 03 : Demographic Characteristics
Full Analysis Dataset : RUSSIA**

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Sex, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	Male	321 (54.8)	347 (53.8)	221 (52.0)	223 (47.2)	1112 (52.3)	889 (53.7)
	Female	265 (45.2)	298 (46.2)	204 (48.0)	249 (52.8)	1016 (47.7)	767 (46.3)
Age at Diagnosis (Years)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	Mean (SD)	64.3 (10.6)	65.1 (11.0)	64.5 (11.2)	65.8 (10.9)	64.9 (10.9)	64.7 (10.9)
	Median (IQR)	64.0 (57.0 to 73.0)	65.0 (58.0 to 74.0)	64.0 (57.0 to 73.0)	65.0 (58.0 to 75.0)	65.0 (58.0 to 74.0)	64.0 (57.0 to 73.5)
	Min to Max	32 to 89	22 to 91	31 to 92	33 to 100	22 to 100	22 to 92
Age Group, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	<65	300 (51.2)	310 (48.1)	223 (52.5)	223 (47.2)	1056 (49.6)	833 (50.3)
	65-74	177 (30.2)	191 (29.6)	113 (26.6)	123 (26.1)	604 (28.4)	481 (29.0)
	>=75	109 (18.6)	144 (22.3)	89 (20.9)	126 (26.7)	468 (22.0)	342 (20.7)
Time since AF Diagnosis (Weeks)	n (missing)	550 (36)	574 (71)	385 (40)	430 (42)	1939 (189)	1509 (147)
	Mean (SD)	2.09 (1.68)	1.87 (1.46)	1.61 (1.35)	1.84 (1.59)	1.87 (1.54)	1.88 (1.53)
	Median (IQR)	1.50 (0.80 to 3.10)	1.50 (0.80 to 2.50)	1.20 (0.70 to 2.10)	1.40 (0.70 to 2.40)	1.40 (0.70 to 2.50)	1.40 (0.80 to 2.70)
	Min to Max	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	Caucasian	513 (87.5)	640 (99.2)	422 (99.3)	468 (99.2)	2043 (96.0)	1575 (95.1)
	Hispanic/Latino	-	1 (0.2)	-	-	1 (0.0)	1 (0.1)
	Asian (Not Chinese)	20 (3.4)	-	1 (0.2)	4 (0.8)	25 (1.2)	21 (1.3)

**Table 03 : Demographic Characteristics
Full Analysis Dataset : RUSSIA**

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
	Mixed/Other	53 (9.0)	4 (0.6)	2 (0.5)	-	59 (2.8)	59 (3.6)
Region, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	Europe	586 (100.0)	645 (100.0)	425 (100.0)	472 (100.0)	2128 (100.0)	1656 (100.0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : RUSSIA**

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	Internal Medicine	92 (15.7)	88 (13.6)	40 (9.4)	56 (11.9)	276 (13.0)	220 (13.3)
	Cardiology	404 (68.9)	515 (79.8)	344 (80.9)	363 (76.9)	1626 (76.4)	1263 (76.3)
	Neurology	3 (0.5)	2 (0.3)	2 (0.5)	2 (0.4)	9 (0.4)	7 (0.4)
	Geriatrics	-	1 (0.2)	-	1 (0.2)	2 (0.1)	1 (0.1)
	Primary Care/General Practice	87 (14.8)	39 (6.0)	39 (9.2)	50 (10.6)	215 (10.1)	165 (10.0)
Care Setting Location at Diagnosis, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	Hospital	469 (80.0)	512 (79.4)	363 (85.4)	402 (85.2)	1746 (82.0)	1344 (81.2)
	Office	88 (15.0)	118 (18.3)	46 (10.8)	34 (7.2)	286 (13.4)	252 (15.2)
	Anticoagulation clinic/thrombosi s centre	-	-	1 (0.2)	2 (0.4)	3 (0.1)	1 (0.1)
	Emergency room	29 (4.9)	15 (2.3)	15 (3.5)	34 (7.2)	93 (4.4)	59 (3.6)
Type of AF Diagnosed, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	Permanent	56 (9.6)	50 (7.8)	10 (2.4)	15 (3.2)	131 (6.2)	116 (7.0)
	Persistent	97 (16.6)	113 (17.5)	49 (11.5)	66 (14.0)	325 (15.3)	259 (15.6)
	Paroxysmal	194 (33.1)	191 (29.6)	114 (26.8)	125 (26.5)	624 (29.3)	499 (30.1)
	New	239 (40.8)	291 (45.1)	252 (59.3)	266 (56.4)	1048 (49.2)	782 (47.2)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : RUSSIA**

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Treatment Costs, n(%)	n (missing)	543 (0)	592 (0)	425 (0)	470 (0)	2030 (0)	1560 (0)
	Public insurance	487 (89.7)	557 (94.1)	413 (97.2)	465 (98.9)	1922 (94.7)	1457 (93.4)
	Private (insurance)	12 (2.2)	4 (0.7)	1 (0.2)	1 (0.2)	18 (0.9)	17 (1.1)
	Private (out of pocket)	25 (4.6)	25 (4.2)	10 (2.4)	4 (0.9)	64 (3.2)	60 (3.8)
	Combination	19 (3.5)	6 (1.0)	1 (0.2)	-	26 (1.3)	26 (1.7)
	Unknown	43	53	-	2	98	96
Treatment Sector, n(%)	n (missing)	580 (0)	636 (0)	425 (0)	472 (0)	2113 (0)	1641 (0)
	In the public sector	548 (94.5)	597 (93.9)	393 (92.5)	452 (95.8)	1990 (94.2)	1538 (93.7)
	In the private sector	32 (5.5)	39 (6.1)	32 (7.5)	20 (4.2)	123 (5.8)	103 (6.3)
	Unknown	6	9	-	-	15	15

Table 05 : Vital signs and life style
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Height (cm)	n (missing)	553 (33)	600 (45)	365 (60)	410 (62)	1928 (200)	1518 (138)
	Mean (SD)	169.1 (9.5)	169.7 (9.4)	169.7 (9.7)	168.4 (9.3)	169.3 (9.5)	169.5 (9.5)
	Median (IQR)	170.0 (162.0 to 176.0)	170.0 (163.0 to 176.0)	170.0 (163.0 to 176.0)	168.0 (162.0 to 176.0)	170.0 (162.0 to 176.0)	170.0 (163.0 to 176.0)
	Min to Max	147 to 196	148 to 202	147 to 201	150 to 198	147 to 202	147 to 202
Weight (kg)	n (missing)	553 (33)	600 (45)	365 (60)	410 (62)	1928 (200)	1518 (138)
	Mean (SD)	85.1 (17.3)	86.2 (17.6)	86.6 (17.9)	85.2 (17.4)	85.8 (17.5)	85.9 (17.6)
	Median (IQR)	82.0 (73.0 to 95.0)	83.0 (74.0 to 96.0)	84.0 (74.0 to 100.0)	82.0 (74.0 to 95.0)	83.0 (74.0 to 96.0)	83.0 (74.0 to 96.0)
	Min to Max	48 to 164	48 to 165	50 to 148	37 to 151	37 to 165	48 to 165
BMI (kg/m ²)	n (missing)	553 (33)	600 (45)	365 (60)	410 (62)	1928 (200)	1518 (138)
	Mean (SD)	29.7 (5.4)	29.9 (5.7)	30.1 (5.5)	30.0 (5.4)	29.9 (5.5)	29.9 (5.5)
	Median (IQR)	29.0 (26.0 to 33.0)	29.0 (26.0 to 33.0)	29.0 (26.0 to 33.0)	29.0 (26.0 to 33.0)	29.0 (26.0 to 33.0)	29.0 (26.0 to 33.0)
	Min to Max	19 to 50	17 to 67	18 to 48	16 to 48	16 to 67	17 to 67
BMI Category, n(%)	n (missing)	553 (33)	600 (45)	365 (60)	410 (62)	1928 (200)	1518 (138)
	<19	-	3 (0.5)	1 (0.3)	3 (0.7)	7 (0.4)	4 (0.3)
	19-<25	109 (19.7)	103 (17.2)	59 (16.2)	65 (15.9)	336 (17.4)	271 (17.9)
	25-<30	206 (37.3)	230 (38.3)	139 (38.1)	162 (39.5)	737 (38.2)	575 (37.9)
	30-<40	213 (38.5)	236 (39.3)	143 (39.2)	160 (39.0)	752 (39.0)	592 (39.0)
	>=40	25 (4.5)	28 (4.7)	23 (6.3)	20 (4.9)	96 (5.0)	76 (5.0)
Pulse (bpm)	n (missing)	577 (9)	644 (1)	407 (18)	464 (8)	2092 (36)	1628 (28)
	Mean (SD)	80.8 (20.5)	83.1 (22.9)	82.2 (21.8)	78.5 (20.0)	81.3 (21.5)	82.1 (21.8)
	Median (IQR)	76.0 (66.0 to 90.0)	77.0 (66.0 to 90.0)	76.0 (67.0 to 90.0)	73.0 (64.0 to 87.5)	75.0 (66.0 to 90.0)	76.0 (66.0 to 90.0)
	Min to Max	46 to 171	48 to 160	50 to 200	40 to 170	40 to 200	46 to 200

Table 05 : Vital signs and life style
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Systolic BP (mm Hg)	n (missing)	577 (9)	644 (1)	411 (14)	463 (9)	2095 (33)	1632 (24)
	Mean (SD)	132.9 (16.3)	131.6 (16.3)	132.7 (17.5)	133.3 (19.2)	132.5 (17.2)	132.3 (16.6)
	Median (IQR)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)
	Min to Max	80 to 180	90 to 190	70 to 220	60 to 240	60 to 240	70 to 220
Diastolic BP (mm Hg)	n (missing)	577 (9)	644 (1)	411 (14)	463 (9)	2095 (33)	1632 (24)
	Mean (SD)	80.8 (9.3)	80.1 (9.1)	79.5 (10.1)	80.1 (10.5)	80.2 (9.7)	80.2 (9.4)
	Median (IQR)	80.0 (72.0 to 90.0)	80.0 (72.0 to 87.5)	80.0 (70.0 to 85.0)	80.0 (74.0 to 87.0)	80.0 (71.0 to 90.0)	80.0 (70.0 to 90.0)
	Min to Max	40 to 114	50 to 110	40 to 120	44 to 120	40 to 120	40 to 120
LVEF (%)	n (missing)	429 (157)	493 (152)	311 (114)	371 (101)	1604 (524)	1233 (423)
	Mean (SD)	57.8 (10.2)	58.2 (9.7)	57.6 (9.8)	58.9 (10.4)	58.1 (10.0)	57.9 (9.9)
	Median (IQR)	60.0 (53.0 to 64.0)	59.0 (53.0 to 65.0)	60.0 (52.0 to 64.0)	60.0 (55.0 to 65.0)	60.0 (53.0 to 65.0)	59.0 (53.0 to 64.0)
	Min to Max	20 to 84	20 to 83	22 to 84	20 to 86	20 to 86	20 to 84
LVEF Category, n (n(%))	n (missing)	429 (157)	493 (152)	311 (114)	371 (101)	1604 (524)	1233 (423)
	<40%	22 (5.1)	24 (4.9)	15 (4.8)	17 (4.6)	78 (4.9)	61 (4.9)
	>=40%	407 (94.9)	469 (95.1)	296 (95.2)	354 (95.4)	1526 (95.1)	1172 (95.1)
History of Hypertension, n(%)	n (missing)	586 (0)	645 (0)	424 (0)	469 (0)	2124 (0)	1655 (0)
	No	44 (7.5)	47 (7.3)	43 (10.1)	45 (9.6)	179 (8.4)	134 (8.1)
	Yes	542 (92.5)	598 (92.7)	381 (89.9)	424 (90.4)	1945 (91.6)	1521 (91.9)

Table 05 : Vital signs and life style
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
	Unknown	-	-	1	3	4	1
Alcohol Consumption, n(%)	n (missing)	501 (0)	621 (0)	423 (0)	468 (0)	2013 (0)	1545 (0)
	Abstinent	263 (52.5)	304 (49.0)	206 (48.7)	261 (55.8)	1034 (51.4)	773 (50.0)
	Light	175 (34.9)	224 (36.1)	163 (38.5)	139 (29.7)	701 (34.8)	562 (36.4)
	Moderate	56 (11.2)	83 (13.4)	45 (10.6)	53 (11.3)	237 (11.8)	184 (11.9)
	Heavy	7 (1.4)	10 (1.6)	9 (2.1)	15 (3.2)	41 (2.0)	26 (1.7)
	Unknown	85	24	2	4	115	111
Smoker, n(%)	n (missing)	564 (0)	629 (0)	422 (0)	469 (0)	2084 (0)	1615 (0)
	No	419 (74.3)	438 (69.6)	317 (75.1)	345 (73.6)	1519 (72.9)	1174 (72.7)
	Ex-smoker	70 (12.4)	81 (12.9)	59 (14.0)	61 (13.0)	271 (13.0)	210 (13.0)
	Current smoker	75 (13.3)	110 (17.5)	46 (10.9)	63 (13.4)	294 (14.1)	231 (14.3)
	Unknown	22	16	3	3	44	41

Table 06 : Clinical History
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Congestive heart failure, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	No	278 (47.4)	331 (51.3)	218 (51.3)	217 (46.0)	1044 (49.1)	827 (49.9)
	Yes	308 (52.6)	314 (48.7)	207 (48.7)	255 (54.0)	1084 (50.9)	829 (50.1)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	304 (278)	311 (331)	203 (218)	254 (217)	1072 (1044)	818 (827)
	I	52 (17.1)	61 (19.6)	29 (14.3)	55 (21.7)	197 (18.4)	142 (17.4)
	II	178 (58.6)	179 (57.6)	116 (57.1)	146 (57.5)	619 (57.7)	473 (57.8)
	III	71 (23.4)	67 (21.5)	53 (26.1)	49 (19.3)	240 (22.4)	191 (23.3)
	IV	3 (1.0)	4 (1.3)	5 (2.5)	4 (1.6)	16 (1.5)	12 (1.5)
	Unknown	4	3	4	1	12	11
Coronary artery disease, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	No	301 (51.4)	297 (46.0)	216 (50.8)	221 (46.8)	1035 (48.6)	814 (49.2)
	Yes	285 (48.6)	348 (54.0)	209 (49.2)	251 (53.2)	1093 (51.4)	842 (50.8)
Acute coronary syndrome, n(%)	n (missing)	586 (0)	642 (0)	423 (0)	469 (0)	2120 (0)	1651 (0)
	No	516 (88.1)	560 (87.2)	370 (87.5)	415 (88.5)	1861 (87.8)	1446 (87.6)
	Yes	70 (11.9)	82 (12.8)	53 (12.5)	54 (11.5)	259 (12.2)	205 (12.4)
	Unknown	-	3	2	3	8	5
Carotid Occlusive Disease, n(%)	n (missing)	586 (0)	623 (0)	412 (0)	464 (0)	2085 (0)	1621 (0)
	No	565 (96.4)	570 (91.5)	395 (95.9)	451 (97.2)	1981 (95.0)	1530 (94.4)

Table 06 : Clinical History
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
	Yes	21 (3.6)	53 (8.5)	17 (4.1)	13 (2.8)	104 (5.0)	91 (5.6)
	Unknown	-	22	13	8	43	35
PE or DVT, n(%)	n (missing)	586 (0)	637 (0)	423 (0)	471 (0)	2117 (0)	1646 (0)
	No	575 (98.1)	628 (98.6)	417 (98.6)	466 (98.9)	2086 (98.5)	1620 (98.4)
	Yes	11 (1.9)	9 (1.4)	6 (1.4)	5 (1.1)	31 (1.5)	26 (1.6)
	Unknown	-	8	2	1	11	10
Other Thromboemboli sm, n(%)	n (missing)	586 (0)	0 (645)	0 (425)	0 (472)	586 (1542)	586 (1070)
	No	584 (99.7)	-	-	-	584 (99.7)	584 (99.7)
	Yes	2 (0.3)	-	-	-	2 (0.3)	2 (0.3)
Systemic Embolization, n(%)	n (missing)	586 (0)	643 (0)	424 (0)	471 (0)	2124 (0)	1653 (0)
	No	585 (99.8)	643 (100.0)	421 (99.3)	469 (99.6)	2118 (99.7)	1649 (99.8)
	Yes	1 (0.2)	-	3 (0.7)	2 (0.4)	6 (0.3)	4 (0.2)
	Unknown	-	2	1	1	4	3
Coronary Artery Bypass Graft, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	No	580 (99.0)	638 (98.9)	420 (98.8)	469 (99.4)	2107 (99.0)	1638 (98.9)
	Yes	6 (1.0)	7 (1.1)	5 (1.2)	3 (0.6)	21 (1.0)	18 (1.1)
Stroke/TIA, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	No	530 (90.4)	594 (92.1)	392 (92.2)	440 (93.2)	1956 (91.9)	1516 (91.5)

Table 06 : Clinical History
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
	Yes	56 (9.6)	51 (7.9)	33 (7.8)	32 (6.8)	172 (8.1)	140 (8.5)
Stroke, n(%)	n (missing)	586 (0)	644 (0)	425 (0)	472 (0)	2127 (0)	1655 (0)
	No	539 (92.0)	601 (93.3)	396 (93.2)	446 (94.5)	1982 (93.2)	1536 (92.8)
	Yes	47 (8.0)	43 (6.7)	29 (6.8)	26 (5.5)	145 (6.8)	119 (7.2)
	Unknown	-	1	-	-	1	1
History of Bleeding, n(%)	n (missing)	586 (0)	643 (0)	425 (0)	472 (0)	2126 (0)	1654 (0)
	No	570 (97.3)	619 (96.3)	413 (97.2)	467 (98.9)	2069 (97.3)	1602 (96.9)
	Yes	16 (2.7)	24 (3.7)	12 (2.8)	5 (1.1)	57 (2.7)	52 (3.1)
	Unknown	-	2	-	-	2	2
Hypercholester olaemia, n(%)	n (missing)	586 (0)	589 (0)	369 (0)	442 (0)	1986 (0)	1544 (0)
	No	282 (48.1)	239 (40.6)	151 (40.9)	200 (45.2)	872 (43.9)	672 (43.5)
	Yes	304 (51.9)	350 (59.4)	218 (59.1)	242 (54.8)	1114 (56.1)	872 (56.5)
	Unknown	-	56	56	30	142	112
Diabetes, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	No	492 (84.0)	536 (83.1)	355 (83.5)	394 (83.5)	1777 (83.5)	1383 (83.5)
	Type I	-	-	-	2 (0.4)	2 (0.1)	-
	Type II	94 (16.0)	109 (16.9)	70 (16.5)	76 (16.1)	349 (16.4)	273 (16.5)
Diabetes, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	No	492 (84.0)	536 (83.1)	355 (83.5)	394 (83.5)	1777 (83.5)	1383 (83.5)
	Yes	94 (16.0)	109 (16.9)	70 (16.5)	78 (16.5)	351 (16.5)	273 (16.5)
Cirrhosis, n(%)	n (missing)	586 (0)	644 (0)	421 (0)	470 (0)	2121 (0)	1651 (0)
	No	585 (99.8)	644 (100.0)	421 (100.0)	470 (100.0)	2120 (100.0)	1650 (99.9)
	Yes	1 (0.2)	-	-	-	1 (0.0)	1 (0.1)

Table 06 : Clinical History
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
	Unknown	-	1	4	2	7	5
Dementia, n(%)	n (missing)	586 (0)	644 (0)	425 (0)	472 (0)	2127 (0)	1655 (0)
	No	583 (99.5)	634 (98.4)	424 (99.8)	471 (99.8)	2112 (99.3)	1641 (99.2)
	Yes	3 (0.5)	10 (1.6)	1 (0.2)	1 (0.2)	15 (0.7)	14 (0.8)
	Unknown	-	1	-	-	1	1
Hyperthyroidism, n(%)	n (missing)	586 (0)	621 (0)	403 (0)	452 (0)	2062 (0)	1610 (0)
	No	583 (99.5)	618 (99.5)	401 (99.5)	449 (99.3)	2051 (99.5)	1602 (99.5)
	Yes	3 (0.5)	3 (0.5)	2 (0.5)	3 (0.7)	11 (0.5)	8 (0.5)
	Unknown	-	24	22	20	66	46
Hypothyroidism, n(%)	n (missing)	586 (0)	619 (0)	401 (0)	452 (0)	2058 (0)	1606 (0)
	No	568 (96.9)	596 (96.3)	386 (96.3)	430 (95.1)	1980 (96.2)	1550 (96.5)
	Yes	18 (3.1)	23 (3.7)	15 (3.7)	22 (4.9)	78 (3.8)	56 (3.5)
	Unknown	-	26	24	20	70	50
Vascular Disease, n(%)	n (missing)	586 (0)	644 (1)	424 (1)	470 (2)	2124 (4)	1654 (2)
	No	472 (80.5)	502 (78.0)	352 (83.0)	392 (83.4)	1718 (80.9)	1326 (80.2)
	Yes	114 (19.5)	142 (22.0)	72 (17.0)	78 (16.6)	406 (19.1)	328 (19.8)
Moderate to Severe CKD, n(%)	n (missing)	586 (0)	645 (0)	425 (0)	472 (0)	2128 (0)	1656 (0)
	No	547 (93.3)	587 (91.0)	373 (87.8)	394 (83.5)	1901 (89.3)	1507 (91.0)
	Yes	39 (6.7)	58 (9.0)	52 (12.2)	78 (16.5)	227 (10.7)	149 (9.0)

Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Baseline Treatment, n(%)	n (missing)	571 (0)	640 (0)	423 (0)	470 (0)	2104 (0)	1634 (0)
	VKA	124 (21.7)	173 (27.0)	100 (23.6)	85 (18.1)	482 (22.9)	397 (24.3)
	VKA+AP	68 (11.9)	52 (8.1)	10 (2.4)	23 (4.9)	153 (7.3)	130 (8.0)
	FXA	8 (1.4)	57 (8.9)	61 (14.4)	90 (19.1)	216 (10.3)	126 (7.7)
	FXA+AP	17 (3.0)	19 (3.0)	11 (2.6)	11 (2.3)	58 (2.8)	47 (2.9)
	DTI	32 (5.6)	43 (6.7)	62 (14.7)	65 (13.8)	202 (9.6)	137 (8.4)
	DTI+AP	18 (3.2)	6 (0.9)	8 (1.9)	12 (2.6)	44 (2.1)	32 (2.0)
	AP	254 (44.5)	221 (34.5)	112 (26.5)	120 (25.5)	707 (33.6)	587 (35.9)
	NONE	50 (8.8)	69 (10.8)	59 (13.9)	64 (13.6)	242 (11.5)	178 (10.9)
	Unknown	15	5	2	2	24	22
	VKA±AP	192 (33.6)	225 (35.2)	110 (26.0)	108 (23.0)	635 (30.2)	527 (32.3)
	FXA±AP	25 (4.4)	76 (11.9)	72 (17.0)	101 (21.5)	274 (13.0)	173 (10.6)
	DTI±AP	50 (8.8)	49 (7.7)	70 (16.5)	77 (16.4)	246 (11.7)	169 (10.3)
	FXA/DTI	40 (7.0)	100 (15.6)	123 (29.1)	155 (33.0)	418 (19.9)	263 (16.1)
	FXA/DTI+AP	35 (6.1)	25 (3.9)	19 (4.5)	23 (4.9)	102 (4.8)	79 (4.8)
	FXA/DTI±AP	75 (13.1)	125 (19.5)	142 (33.6)	178 (37.9)	520 (24.7)	342 (20.9)
	AC	164 (28.7)	273 (42.7)	223 (52.7)	240 (51.1)	900 (42.8)	660 (40.4)
	AC+AP	103 (18.0)	77 (12.0)	29 (6.9)	46 (9.8)	255 (12.1)	209 (12.8)
	AC±AP	267 (46.8)	350 (54.7)	252 (59.6)	286 (60.9)	1155 (54.9)	869 (53.2)

Table 08: Treatment
Full Analysis Dataset : RUSSIA

	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
Anti-platelet (non mutually exclusive groups)						
Glycoprotein inhibitors	3 (0.5)	-	-		3 (0.1)	3 (0.2)
ADP receptor/P2Y12 inhibitors	49 (8.4)	45 (7.0)	21 (4.9)	28 (5.9)	143 (6.7)	115 (6.9)
Prostaglandin Cox inhibitors	-	1 (0.2)	-		1 (0.0)	1 (0.1)
ASA	-	89 (13.8)	14 (3.3)	6 (1.3)	109 (5.1)	103 (6.2)
	325 (55.5)	219 (34.0)	131 (30.8)	162 (34.3)	837 (39.3)	675 (40.8)
Anticoagulant drugs (non mutually exclusive groups)						
VKA	202 (34.5)	227 (35.2)	110 (25.9)	109 (23.1)	648 (30.5)	539 (32.5)
FXa	35 (6.0)	77 (11.9)	74 (17.4)	103 (21.8)	289 (13.6)	186 (11.2)
DTI	52 (8.9)	50 (7.8)	72 (16.9)	78 (16.5)	252 (11.8)	174 (10.5)
Heparinoid	16 (2.7)	4 (0.6)	2 (0.5)	1 (0.2)	23 (1.1)	22 (1.3)
Heparins	129 (22.0)	114 (17.7)	97 (22.8)	67 (14.2)	407 (19.1)	340 (20.5)
Other	-	1 (0.2)	-	3 (0.6)	4 (0.2)	1 (0.1)

Table 09 : Risk scores
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
CHADS2 Score	n (missing)	585 (1)	645 (0)	423 (2)	468 (4)	2121 (7)	1653 (3)
	Mean (SD)	2.0 (1.1)	2.0 (1.0)	1.9 (1.0)	2.0 (1.0)	2.0 (1.1)	2.0 (1.1)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)
	Min to Max	0 to 5	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	585 (1)	645 (0)	423 (2)	468 (4)	2121 (7)	1653 (3)
	0	21 (3.6)	22 (3.4)	18 (4.3)	12 (2.6)	73 (3.4)	61 (3.7)
	1	166 (28.4)	221 (34.3)	137 (32.4)	143 (30.6)	667 (31.4)	524 (31.7)
	2	241 (41.2)	224 (34.7)	165 (39.0)	184 (39.3)	814 (38.4)	630 (38.1)
	3	101 (17.3)	126 (19.5)	77 (18.2)	91 (19.4)	395 (18.6)	304 (18.4)
	4	36 (6.2)	40 (6.2)	15 (3.5)	30 (6.4)	121 (5.7)	91 (5.5)
	5	20 (3.4)	11 (1.7)	9 (2.1)	5 (1.1)	45 (2.1)	40 (2.4)
	6	-	1 (0.2)	2 (0.5)	3 (0.6)	6 (0.3)	3 (0.2)
CHA2DS2- VASc Score	n (missing)	585 (1)	642 (3)	421 (4)	465 (7)	2113 (15)	1648 (8)
	Mean (SD)	3.2 (1.6)	3.2 (1.6)	3.1 (1.6)	3.3 (1.6)	3.2 (1.6)	3.1 (1.6)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 8	0 to 9	0 to 9	0 to 9	0 to 9
CHA2DS2- VASc score categories, n(%)	n (missing)	585 (1)	642 (3)	421 (4)	465 (7)	2113 (15)	1648 (8)
	0	16 (2.7)	13 (2.0)	6 (1.4)	2 (0.4)	37 (1.8)	35 (2.1)
	1	65 (11.1)	99 (15.4)	64 (15.2)	62 (13.3)	290 (13.7)	228 (13.8)
	2	125 (21.4)	120 (18.7)	99 (23.5)	101 (21.7)	445 (21.1)	344 (20.9)
	3	165 (28.2)	149 (23.2)	93 (22.1)	98 (21.1)	505 (23.9)	407 (24.7)
	4	92 (15.7)	128 (19.9)	86 (20.4)	100 (21.5)	406 (19.2)	306 (18.6)

Table 09 : Risk scores
Full Analysis Dataset : RUSSIA

Variable	Statistics	Cohort 2 (N=586) (n %)	Cohort 3 (N=645) (n %)	Cohort 4 (N=425) (n %)	Cohort 5 (N=472) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2128)	Total Prospective patients Cohorts 1 to 4 (N=1656)
	5	70 (12.0)	80 (12.5)	46 (10.9)	67 (14.4)	263 (12.4)	196 (11.9)
	6-9	52 (8.9)	53 (8.3)	27 (6.4)	35 (7.5)	167 (7.9)	132 (8.0)
HAS-BLED score	n (missing)	260 (326)	554 (91)	374 (51)	445 (27)	1633 (495)	1188 (468)
	Mean (SD)	1.3 (0.9)	1.3 (0.9)	1.2 (0.9)	1.3 (0.9)	1.3 (0.9)	1.2 (0.9)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (0.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 4	0 to 4	0 to 4	0 to 4	0 to 4
HAS-BLED score categories, n(%)	n (missing)	260 (326)	554 (91)	374 (51)	445 (27)	1633 (495)	1188 (468)
	0	50 (19.2)	109 (19.7)	97 (25.9)	74 (16.6)	330 (20.2)	256 (21.5)
	1	114 (43.8)	240 (43.3)	146 (39.0)	216 (48.5)	716 (43.8)	500 (42.1)
	2	67 (25.8)	163 (29.4)	102 (27.3)	115 (25.8)	447 (27.4)	332 (27.9)
	3	25 (9.6)	34 (6.1)	26 (7.0)	37 (8.3)	122 (7.5)	85 (7.2)
	4	4 (1.5)	8 (1.4)	3 (0.8)	3 (0.7)	18 (1.1)	15 (1.3)

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : RUSSIA

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	3	21.4	1	7.1	-	-	1	7.1	-	-	-	-	6	42.9	3	21.4	2
	1	9	14.1	9	14.1	1	1.6	1	1.6	3	4.7	3	4.7	31	48.4	7	10.9	1
	2	29	24	18	14.9	3	2.5	1	0.8	7	5.8	-	-	54	44.6	9	7.4	4
	3	37	22.7	19	11.7	3	1.8	8	4.9	7	4.3	7	4.3	72	44.2	10	6.1	2
	4	22	24.4	7	7.8	-	-	3	3.3	12	13.3	4	4.4	33	36.7	9	10	2
	5	17	24.6	9	13	-	-	2	2.9	1	1.4	2	2.9	31	44.9	7	10.1	1
	6-9	7	14.3	5	10.2	1	2	1	2	2	4.1	2	4.1	26	53.1	5	10.2	3
Cohort 3	0	5	38.5	-	-	1	7.7	2	15.4	1	7.7	-	-	3	23.1	1	7.7	-
	1	30	30.6	6	6.1	8	8.2	3	3.1	7	7.1	1	1	29	29.6	14	14.3	1
	2	36	30.3	7	5.9	11	9.2	3	2.5	7	5.9	1	0.8	40	33.6	14	11.8	1
	3	42	28.2	13	8.7	15	10.1	4	2.7	10	6.7	2	1.3	48	32.2	15	10.1	-
	4	29	22.7	11	8.6	16	12.5	2	1.6	7	5.5	1	0.8	49	38.3	13	10.2	-
	5	17	21.8	7	9	3	3.8	1	1.3	8	10.3	-	-	37	47.4	5	6.4	2
	6-9	13	25	7	13.5	3	5.8	4	7.7	3	5.8	1	1.9	14	26.9	7	13.5	1
Cohort 4	0	-	-	-	-	1	16.7	-	-	1	16.7	-	-	2	33.3	2	33.3	-
	1	11	17.5	2	3.2	11	17.5	2	3.2	11	17.5	1	1.6	11	17.5	14	22.2	1
	2	27	27.3	1	1	16	16.2	1	1	14	14.1	1	1	27	27.3	12	12.1	-
	3	16	17.4	4	4.3	16	17.4	3	3.3	15	16.3	2	2.2	27	29.3	9	9.8	1
	4	24	27.9	3	3.5	9	10.5	1	1.2	12	14	1	1.2	23	26.7	13	15.1	-
	5	13	28.3	-	-	6	13	-	-	7	15.2	2	4.3	14	30.4	4	8.7	-
	6-9	9	33.3	-	-	2	7.4	3	11.1	2	7.4	1	3.7	6	22.2	4	14.8	-
Cohort 5	0	-	-	-	-	1	50	-	-	-	-	-	-	-	-	1	50	-
	1	8	12.9	3	4.8	13	21	-	-	7	11.3	-	-	16	25.8	15	24.2	-
	2	13	12.9	6	5.9	11	10.9	4	4	16	15.8	3	3	33	32.7	15	14.9	-
	3	20	20.4	4	4.1	23	23.5	2	2	6	6.1	3	3.1	27	27.6	13	13.3	-
	4	24	24	2	2	22	22	2	2	21	21	1	1	16	16	12	12	-
	5	11	16.4	5	7.5	12	17.9	2	3	10	14.9	4	6	17	25.4	6	9	-
	6-9	8	24.2	1	3	8	24.2	1	3	5	15.2	1	3	7	21.2	2	6.1	2

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : RUSSIA**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 5	0	8	22.9	1	2.9	3	8.6	3	8.6	2	5.7	-	-	11	31.4	7	20	2
	1	58	20.2	20	7	33	11.5	6	2.1	28	9.8	5	1.7	87	30.3	50	17.4	3
	2	105	23.9	32	7.3	41	9.3	9	2	44	10	5	1.1	154	35	50	11.4	5
	3	115	22.9	40	8	57	11.4	17	3.4	38	7.6	14	2.8	174	34.7	47	9.4	3
	4	99	24.5	23	5.7	47	11.6	8	2	52	12.9	7	1.7	121	30	47	11.6	2
	5	58	22.3	21	8.1	21	8.1	5	1.9	26	10	8	3.1	99	38.1	22	8.5	3
	6-9	37	23	13	8.1	14	8.7	9	5.6	12	7.5	5	3.1	53	32.9	18	11.2	6
Total Prospective patients Cohorts 1 to 4	0	8	24.2	1	3	2	6.1	3	9.1	2	6.1	-	-	11	33.3	6	18.2	2
	1	50	22.2	17	7.6	20	8.9	6	2.7	21	9.3	5	2.2	71	31.6	35	15.6	3
	2	92	27.1	26	7.7	30	8.8	5	1.5	28	8.3	2	0.6	121	35.7	35	10.3	5
	3	95	23.5	36	8.9	34	8.4	15	3.7	32	7.9	11	2.7	147	36.4	34	8.4	3
	4	75	24.7	21	6.9	25	8.2	6	2	31	10.2	6	2	105	34.5	35	11.5	2
	5	47	24.4	16	8.3	9	4.7	3	1.6	16	8.3	4	2.1	82	42.5	16	8.3	3
	6-9	29	22.7	12	9.4	6	4.7	8	6.3	7	5.5	4	3.1	46	35.9	16	12.5	4

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : RUSSIA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	33	66	-	-	5	10	-	-	8	16	-	-	-	-	4	8	-
	1	39	34.8	11	9.8	-	-	2	1.8	15	13.4	4	3.6	38	33.9	3	2.7	2
	2	13	19.7	9	13.6	-	-	-	-	3	4.5	2	3	38	57.6	1	1.5	1
	3	-	-	4	16	-	-	1	4	1	4	4	16	14	56	1	4	-
	4-9	-	-	-	-	-	-	1	25	-	-	-	-	3	75	-	-	-
Cohort 3	0	57	52.3	-	-	16	14.7	-	-	13	11.9	-	-	-	-	23	21.1	-
	1	69	29.2	16	6.8	31	13.1	2	0.8	21	8.9	-	-	75	31.8	22	9.3	4
	2	25	15.3	23	14.1	6	3.7	5	3.1	6	3.7	3	1.8	88	54	7	4.3	-
	3	9	26.5	6	17.6	-	-	-	-	2	5.9	-	-	15	44.1	2	5.9	-
	4-9	-	-	4	50	-	-	1	12.5	-	-	-	-	2	25	1	12.5	-
Cohort 4	0	32	33.3	-	-	27	28.1	-	-	17	17.7	-	-	-	-	20	20.8	1
	1	28	19.2	4	2.7	21	14.4	3	2.1	26	17.8	4	2.7	42	28.8	18	12.3	-
	2	20	19.8	1	1	8	7.9	3	3	13	12.9	2	2	39	38.6	15	14.9	1
	3	3	11.5	1	3.8	2	7.7	3	11.5	4	15.4	2	7.7	11	42.3	-	-	-
	4-9	-	-	-	-	-	-	-	-	1	33.3	-	-	2	66.7	-	-	-
Cohort 5	0	18	24.3	-	-	25	33.8	-	-	13	17.6	-	-	-	-	18	24.3	-
	1	42	19.4	9	4.2	38	17.6	4	1.9	35	16.2	4	1.9	59	27.3	25	11.6	-
	2	14	12.3	8	7	21	18.4	3	2.6	10	8.8	5	4.4	37	32.5	16	14	1
	3	7	19.4	4	11.1	2	5.6	2	5.6	5	13.9	3	8.3	13	36.1	-	-	1
	4-9	1	33.3	-	-	-	-	1	33.3	-	-	-	-	1	33.3	-	-	-
Total Prospective patients Cohorts 1 to 5	0	140	42.6	-	-	73	22.2	-	-	51	15.5	-	-	-	-	65	19.8	1
	1	178	25.1	40	5.6	90	12.7	11	1.5	97	13.7	12	1.7	214	30.1	68	9.6	6
	2	72	16.2	41	9.2	35	7.9	11	2.5	32	7.2	12	2.7	202	45.5	39	8.8	3
	3	19	15.7	15	12.4	4	3.3	6	5	12	9.9	9	7.4	53	43.8	3	2.5	1

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : RUSSIA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	4-9	1	5.6	4	22.2	-	-	3	16.7	1	5.6	-	-	8	44.4	1	5.6	-
Total Prospective patients Cohorts 1 to 4	0	122	47.8	-	-	48	18.8	-	-	38	14.9	-	-	-	-	47	18.4	1
	1	136	27.5	31	6.3	52	10.5	7	1.4	62	12.6	8	1.6	155	31.4	43	8.7	6
	2	58	17.6	33	10	14	4.2	8	2.4	22	6.7	7	2.1	165	50	23	7	2
	3	12	14.1	11	12.9	2	2.4	4	4.7	7	8.2	6	7.1	40	47.1	3	3.5	-
	4-9	-	-	4	26.7	-	-	2	13.3	1	6.7	-	-	7	46.7	1	6.7	-

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : RUSSIA**

Variable	Statistics	Cohort 2 (N=192) (n %)	Cohort 3 (N=225) (n %)	Cohort 4 (N=110) (n %)	Total Prospective patients Cohorts 1 to 4 (N=527)
TTR value, n(%)	n (missing)	38 (154)	24 (201)	8 (102)	70 (457)
	<65	19 (50.0)	8 (33.3)	7 (87.5)	34 (48.6)
	>=65	19 (50.0)	16 (66.7)	1 (12.5)	36 (51.4)
TTR	n (missing)	38 (154)	24 (201)	8 (102)	70 (457)
	Mean (SD)	60.1 (34.6)	71.2 (29.0)	38.6 (31.6)	61.4 (33.4)
	Median (IQR)	62.2 (33.7 to 93.1)	75.3 (46.6 to 100.0)	34.9 (14.6 to 54.8)	66.9 (33.7 to 95.1)
	Min to Max	0.0 to 100.0	14.2 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	250	185	47	482
	2-3	141 (56.4)	119 (64.3)	13 (27.7)	273 (56.6)
	<2	83 (33.2)	47 (25.4)	26 (55.3)	156 (32.4)
	>3	26 (10.4)	19 (10.3)	8 (17.0)	53 (11.0)
INR	n	250	185	47	482
	Mean (SD)	2.3 (0.7)	2.4 (1.2)	2.2 (1.3)	2.3 (1.0)
	Median (IQR)	2.3 (1.8 to 2.7)	2.3 (1.9 to 2.6)	1.8 (1.4 to 2.5)	2.2 (1.8 to 2.6)
	Min to Max	0.9 to 6.0	1.0 to 15.0	1.0 to 8.1	0.9 to 15.0

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : RUSSIA**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		1656	48	3.02	(2.27 to 4.00)
	Cardiovascular death	1656	30	1.89	(1.32 to 2.70)
	Non-Cardiovascular death	1656	9	0.57	(0.29 to 1.09)
	Undetermined cause	1656	9	0.57	(0.29 to 1.09)
Stroke/SE		1656	35	2.22	(1.59 to 3.09)
Major bleed		1656	4	0.25	(0.09 to 0.67)
Acute coronary syndrome		1656	22	1.39	(0.91 to 2.11)
Congestive Heart Failure		1656	60	3.86	(3.00 to 4.97)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : RUSSIA**

		RUSSIA		
Outcome	Cause	N	Events	%
Cardiovascular causes	Myocardial infarction	30	9	30.00
	Ischaemic stroke	30	5	16.67
	Congestive heart failure	30	7	23.33
	Sudden or unwitnessed death	30	3	10.00
	Other	30	6	20.00
Non-cardiovascular causes	Infection/sepsis	9	1	11.11
	Malignancy	9	8	88.89

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :RUSSIA**

OUTCOME	RUSSIA		
	N	Events	%
Stroke(not including systemic embolism)	1656	33	1.99
Primary Ischemic Stroke	1656	23	1.39
<i>of which secondary hemorrhagic ischemic</i>	1656	1	0.06
Primary intracerebral hemorrhage*	1656	3	0.18
<i>Intracerebral</i>	1656	1	0.06
<i>Subarachnoid</i>	1656	1	0.06
Undetermined	1656	7	0.42

*Note :Multiple choice question type that allows the respondent to choose one or multiple options from the list of possible answers.

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : RUSSIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	35	33.58	1	2.98	(0.42 to 21.14)
1	228	223.20	1	0.45	(0.06 to 3.18)
2	344	335.72	4	1.19	(0.45 to 3.18)
3	407	389.65	10	2.57	(1.38 to 4.77)
4+	634	600.90	32	5.33	(3.77 to 7.53)
Unknown	8	7.64	0	-	-

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : RUSSIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	35	33.58	0	-	-
1	228	223.20	0	-	-
2	344	333.84	4	1.20	(0.45 to 3.19)
3	407	386.60	8	2.07	(1.04 to 4.14)
4+	634	593.37	23	3.88	(2.58 to 5.83)
Unknown	8	7.64	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : RUSSIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	35	33.58	0	-	-
1	228	223.20	0	-	-
2	344	335.72	0	-	-
3	407	388.73	1	0.26	(0.04 to 1.83)
4+	634	600.41	3	0.50	(0.16 to 1.55)
Unknown	8	7.64	0	-	-